ストックスクリーナーアプリを入手
39.36
0.51%
0.20
前日終値:
$39.16
開ける：
$39.16
24時間の取引高:
1.81M
Relative Volume:
0.61
時価総額：
$6.04B
収益：
-
当期純損益:
$-284.08M
株価収益率:
-16.24
EPS:
-2.4234
ネットキャッシュフロー:
$-234.65M
1週間 パフォーマンス:
-2.55%
1か月 パフォーマンス:
+178.56%
6か月 パフォーマンス:
+597.87%
1年 パフォーマンス:
+327.36%
1日の値動き範囲:
$37.94
$39.58
1週間の範囲:
$37.75
$41.27
52週間の値動き範囲:
$3.72
$41.27
Cogent Biosciences Inc Stock (COGT) Company Profile
COGT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
39.36 | 6.01B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-10 | アップグレード | Stifel | Hold → Buy |
| 2025-11-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Cogent Biosciences Inc a good long term investmentREITs Market Trends & Free Exceptional ROI Methods - earlytimes.in
Can Cogent Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Technicals & High Conviction Buy Zone Alerts - Newser
Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT) - MarketBeat
XTX Topco Ltd Has $836,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Has $94,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Price Target Increased by 93.94% to 43.52 - MSN
Geode Capital Management LLC Raises Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
F m Investments LLC Takes Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Ensign Peak Advisors Inc Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences stock hits 52-week high at 40.76 USD By Investing.com - Investing.com Nigeria
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cogent Biosciences stock hits 52-week high at 40.76 USD - Investing.com
Cogent Biosciences Spends Big As Drug Hopes Build - Finimize
A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results - Sahm
Cogent Biosciences (NASDAQ:COGT) Reaches New 52-Week HighWhat's Next? - MarketBeat
Biotech Star Cogent Rides High On Breakthrough Trial Hopes - Finimize
Cogent Biosciences Announces $230 Million Convertible Senior Notes Offering - Global Legal Chronicle
Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance
Why Cogent Biosciences (COGT) Is Up 18.9% After Positive Phase 3 GIST Trial Results - sahmcapital.com
Cogent Biosciences Completes $345 Million Common Stock Offering and $200 Million Convertible Notes Offering - Global Legal Chronicle
Top Biotech Stocks To ConsiderNovember 20th - MarketBeat
Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Finviz
Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Insider Monkey
10 Hottest SMID-Cap Stocks So Far In 2025 - Insider Monkey
Cogent Biosciences (NASDAQ:COGT) Sets New 12-Month HighStill a Buy? - MarketBeat
Technical Reactions to COGT Trends in Macro Strategies - news.stocktradersdaily.com
Mintz Advises on Cogent Biosciences Inc.’s Concurrent Public Offerings of $345 Million of Common Stock and $230 Million in Aggregate Principal Amount of 1.625% Convertible Senior Notes Due 2031 - Mintz
Cogent Biosciences stock hits 52-week high at 36.31 USD By Investing.com - Investing.com Canada
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Yahoo Finance
Cogent Biosciences stock hits 52-week high at 36.31 USD - Investing.com India
What earnings revisions data tells us about Cogent Biosciences Inc.Earnings Beat & Reliable Trade Execution Plans - newser.com
Cogent Biosciences : COGT Jefferies London 2025 - MarketScreener
A Look at Cogent Biosciences’s Valuation After Positive Phase 3 Data and Major Funding Updates - sahmcapital.com
Comparing Cogent Biosciences Inc. in custom built stock radarsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
Cogent Biosciences Completes $230M Convertible Notes Offering - TipRanks
[8-K] Cogent Biosciences, Inc. Reports Material Event | COGT SEC FilingForm 8-K - Stock Titan
Cogent Biosciences, Inc. Bonds — Corporate Bond Rates - TradingView
Will Cogent Biosciences Inc. stock maintain dividend yield2025 Trading Recap & Risk Controlled Swing Alerts - newser.com
Profund Advisors LLC Has $145,000 Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT6232219 Bond Analysis — Key Metrics - TradingView
COGT6232219 Bond Price and Chart — FINRA:COGT6232219 - TradingView
Cogent Biosciences: Soaring On Blowout GIST DataI Expect More Upside (NASDAQ:COGT) - Seeking Alpha
427,342 Shares in Cogent Biosciences, Inc. $COGT Purchased by Candriam S.C.A. - MarketBeat
FY2025 Earnings Estimate for COGT Issued By HC Wainwright - MarketBeat
10 Market Movers That Made Millionaires in a Week - Insider Monkey
Can Cogent Biosciences Inc. stock rebound after recent weaknessWeekly Profit Report & Expert Approved Trade Ideas - newser.com
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - Finviz
Can Cogent Biosciences Inc. stock weather global recessionWeekly Trading Summary & Real-Time Volume Analysis - newser.com
Is Cogent Biosciences Inc. stock a buy before product launchesJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):